Oxytrol Bladder Drug Patent Suit Settled by Watson, Barr

Watson Laboratories has settled a patent infringement lawsuit with Barr Laboratories over the overactive bladder drug Oxytrol. Watson has granted Barr a royalty-bearing license to the U.S. patents covering Oxytrol (oxybutynin) as part of the agreement. Barr may start marketing its product April 26, 2015, or earlier under certain circumstances.
Generic Line